Literature DB >> 26432667

Cytogenetics in multiple myeloma patients progressing into extramedullary disease.

Lenka Besse1, Lenka Sedlarikova1,2, Henrieta Greslikova1, Renata Kupska1, Martina Almasi2, Miroslav Penka2, Tomas Jelinek3, Ludek Pour4, Zdenek Adam4, Petr Kuglik1, Marta Krejci4, Roman Hajek1,2,3, Sabina Sevcikova1,2.   

Abstract

BACKGROUND: Extramedullary disease in multiple myeloma patients is an uncommon event occurring either at the time of diagnosis, or during disease progression/relapse. This manifestation is frequently associated with poor outcome and resistance to treatment. We evaluated chromosomal alterations of plasma cells of multiple myeloma patients with extramedullary relapse, either in the bone marrow (BM) or at extramedullary sites, and in previous BM collection by interphase fluorescence in situ hybridization.
MATERIAL AND METHODS: Thirty-one patients [25 BM plasma cells (BMPCs), 18 extramedullary tumor plasma cells], of which 12 had paired samples of BM and extramedullary plasma cells and 14 had previous collection of BM, were investigated for the presence of chromosomal aberrations (CHAs): del(17)(p13), del(13)(q14), 14q32 disruption, t(4;14)(p16;q32), t(14;16)(q32;q23), gain(1)(q21), and hyperdiploidy status.
RESULTS: Overall, in unrelated samples, t(4;14) was more prevalent in extramedullary plasma cells, and hyperdiploidy was more frequent in BMPCs. In paired samples, there was a higher frequency of del(13)(q14) and 14q32 disruption in BMPCs. Frequency of all studied CHAs was higher in BMPCs of extramedullary patients than in their previous sample collection.
CONCLUSION: These data show that plasma cells harbor more aberrations during their transformation into extramedullary form.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cytogenetics; extramedullary relapse; multiple myeloma

Mesh:

Substances:

Year:  2015        PMID: 26432667     DOI: 10.1111/ejh.12688

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  17 in total

1.  Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.

Authors:  Chee Man Cheong; Krzysztof M Mrozik; Duncan R Hewett; Elyse Bell; Vasilios Panagopoulos; Jacqueline E Noll; Jonathan D Licht; Stan Gronthos; Andrew C W Zannettino; Kate Vandyke
Journal:  Cancer Lett       Date:  2020-01-31       Impact factor: 8.679

2.  Relapse of Multiple Myeloma Presenting as Lower Lip Numbness.

Authors:  Yusra M Al-Riyami; Abdulaziz Bakathir; Khalil Al-Farsi; Faisal Al-Azri
Journal:  Sultan Qaboos Univ Med J       Date:  2016-11-30

3.  Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion.

Authors:  Yongfeng Zhao; Fuling Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-25       Impact factor: 4.553

4.  Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement.

Authors:  Ignacio Español; Marta Romera; María Dolores Gutiérrez-Meca; Maria Del Carmen García; Aurelia Tejedor; Antonio Martínez; Jerónima Ibáñez; Felipe De Arriba; Alfredo Minguela; Teodoro Iturbe; Maria Dolores López
Journal:  Clin Case Rep       Date:  2017-06-22

Review 5.  Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma.

Authors:  Benjamin G Barwick; Vikas A Gupta; Paula M Vertino; Lawrence H Boise
Journal:  Front Immunol       Date:  2019-05-21       Impact factor: 7.561

6.  Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease.

Authors:  Xiang Zhou; Patricia Flüchter; Katharina Nickel; Katharina Meckel; Janin Messerschmidt; David Böckle; Sebastian Knorz; Maximilian Johannes Steinhardt; Franziska Krummenast; Sophia Danhof; Hermann Einsele; K Martin Kortüm; Leo Rasche
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

7.  Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma.

Authors:  Juan Xu; Nanhui Yu; Pan Zhao; Fangfang Wang; Jingcao Huang; Yushan Cui; Hong Ding; Yan Yang; Yuhan Gao; Ling Pan; Hong Chang; Yu Wu; Bing Xiang; Yuping Gong; Xiao Shuai; Li Hou; Liping Xie; Ting Niu; Ting Liu; Li Zhang; Weiping Liu; Wenyan Zhang; Ying Qu; Wei Lin; Yimin Zhu; Sha Zhao; Yuhuan Zheng
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

8.  Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies.

Authors:  Lourdes Farre; Gabriela Sanz; Neus Ruiz-Xivillé; Manuel Castro de Moura; Juan Francisco Martin-Tejera; Samuel Gonçalves-Ribeiro; Maria Martinez-Iniesta; Monica Calaf; Jose Luis Mosquera; José Ignacio Martín-Subero; Isabel Granada; Manel Esteller; Eva Domingo-Domenech; Fina Climent; Alberto Villanueva; Anna Sureda
Journal:  Dis Model Mech       Date:  2021-07-15       Impact factor: 5.758

9.  Identification of patients at high risk of secondary extramedullary multiple myeloma development.

Authors:  Martin Stork; Sabina Sevcikova; Jiri Minarik; Petra Krhovska; Jakub Radocha; Lenka Pospisilova; Lucie Brozova; Jiri Jarkovsky; Ivan Spicka; Jan Straub; Petr Pavlicek; Alexandra Jungova; Tomas Jelinek; Viera Sandecka; Vladimir Maisnar; Roman Hajek; Ludek Pour
Journal:  Br J Haematol       Date:  2021-11-02       Impact factor: 8.615

10.  Pericardial relapse of multiple myeloma.

Authors:  Lee S Jamison; Clifton Craig Mo; Mary Kwok
Journal:  BMJ Case Rep       Date:  2020-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.